The potential of FcγRIIB in immunotherapy

We exclusively interview Dr Ali Roghanian, Associate Professor at the University of Southampton, UK, Ali is a leading researcher at the forefront of immunotherapy advancements. With a keen focus on the inhibitory IgG FcγRIIB receptor, join us as we dive into Ali’s findings, showcasing the complexities of FcγRIIB and its potential to revolutionise therapeutic approaches.